Cargando…

ESKALE study, a French real-world study describing TRD patients with Esketamine nasal spray: final analysis

INTRODUCTION: Treatment resistant depression (TRD) affects a substantial proportion of patients with depression and carries a large unmet need. Esketamine nasal spray (NS), in combination with a selective serotonin reuptake inhibitor (SSRI) or serotonin norepinephrine reuptake inhibitor (SNRI), has...

Descripción completa

Detalles Bibliográficos
Autores principales:	Samalin, L., Mekaoui, L., Rotharmel, M., de Maricourt, P., Codet, M.-A., Gaudre Wattinne, E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cambridge University Press 2023
Materias:	Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10596582/ http://dx.doi.org/10.1192/j.eurpsy.2023.271

Ejemplares similares

ESKALE study, a French real-world study of esketamine nasal spray for patients with treatment-resistant depression
por: Ludovic, S., et al.
Publicado: (2022)

Esketamine in patient with treatment resistant depression: Outcome of the temporary authorization for use programme in France
por: Wattinne, E. Gaudre, et al.
Publicado: (2021)

Adverse Events and Measurement of Dissociation After the First Dose of Esketamine in Patients With TRD
por: Williamson, David, et al.
Publicado: (2022)

Benefit–Risk Assessment of Esketamine Nasal Spray vs. Placebo in Treatment‐Resistant Depression
por: Katz, Eva G., et al.
Publicado: (2020)

Managing dissociative symptoms following the use of esketamine nasal spray: a case report
por: Pereira, Sophia, et al.
Publicado: (2020)

Relationship Between Dissociation and Antidepressant Effects of Esketamine Nasal Spray in Patients With Treatment-Resistant Depression
por: Chen, Guang, et al.
Publicado: (2022)

Eskalations‑/Deeskalationskonzept zur COVID-19-bedingten Freihaltung von Intensivkapazitäten an Kliniken
por: Pfenninger, E. G., et al.
Publicado: (2021)

Improvement of functional neurological disorder after administration of esketamine nasal spray: a case report
por: Vendrell-Serres, Júlia, et al.
Publicado: (2021)

Pattern recognition in TRD/Tracker (TRD/T)
por: Gavrilenko, I
Publicado: (1992)

Esketamine nasal spray shows higher remission and response rates over 32 weeks of treatment compared with quetiapine extended-release in patients with treatment resistant depression: Results from ESCAPE-TRD, a randomised, phase IIIb clinical trial
por: Reif, A., et al.
Publicado: (2023)

Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program
por: Doherty, Teodora, et al.
Publicado: (2020)

Real-world approach to managing dysgeusia following the use of esketamine nasal spray: a case report
por: Bossaller, Nicholas A., et al.
Publicado: (2020)

Pitfalls of Cost-Effectiveness Analysis in Practice: A TRD Case Example in the United States with Esketamine Versus Oral Antidepressants
por: Karkare, Swapna, et al.
Publicado: (2020)

Esketamine Nasal Spray Improves Rate and Time to Remission Versus Quetiapine Extended Release in Subgroups of Patients With Treatment Resistant Depression and Two or Three Plus Prior Treatment Failures: Results From ESCAPE-TRD, a Randomised Phase IIIb Trial
por: Young, A.H., et al.
Publicado: (2023)

Esketamine Nasal Spray for the Rapid Reduction of Depressive Symptoms in Major Depressive Disorder With Acute Suicidal Ideation or Behavior
por: Canuso, Carla M., et al.
Publicado: (2021)

Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 study
por: Zaki, Naim, et al.
Publicado: (2023)

Early Clinical Experiences of Esketamine Nasal Spray in the UK in Adults with Treatment-Resistant Major Depressive Disorder: Advisory Panel Recommendations
por: Young, Allan H, et al.
Publicado: (2023)

TRD Occupancies
por: Hawkings, R J, et al.
Publicado: (1993)

The HELIOS TRD
por: Clemen, M
Publicado: (1989)

Treatment Response of Add-On Esketamine Nasal Spray in Resistant Major Depression in Relation to Add-On Second-Generation Antipsychotic Treatment
por: Dold, Markus, et al.
Publicado: (2020)

Treating with esketamine nasal, will increase blood pressure?
por: Rosello-Molina, V., et al.
Publicado: (2021)

ALICE TRD under test, view of the TRD test beam.
Publicado: (2002)

Effects of preoperative nasal spray esketamine on separation anxiety and emergence agitation in pediatric strabismus surgery: A randomized clinical trial
por: Liu, Wei, et al.
Publicado: (2022)

ALICE Transition Radiation Detector (TRD) time expansion chambers of TRD
Publicado: (2003)

Assessing the meaningful change threshold of Quality of Life in Depression Scale using data from two phase 3 studies of esketamine nasal spray
por: Rozjabek, Heather, et al.
Publicado: (2022)

Triggering with the ALICE TRD
por: Klein, Jochen
Publicado: (2011)

Physics with the ALICE TRD
por: Vulpescu, B
Publicado: (2002)

Efficacy and safety of esketamine nasal spray by sex in patients with treatment-resistant depression: findings from short-term randomized, controlled trials
por: Jones, Robyn R., et al.
Publicado: (2022)

Safety of esketamine nasal spray: Analysis of post-marketing reports submitted to the FDA adverse event reporting system in the first year on the market
por: Gastaldon, C., et al.
Publicado: (2021)

Final version of the analog front-end electronics for the ALICE TPC-detector and ALICE TRD-detector
por: Soltveit, H K, et al.
Publicado: (2003)

Effect of Esketamine Nasal Spray on Olfactory Function and Nasal Tolerability in Patients with Treatment-Resistant Depression: Results from Four Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Studies
por: Doty, Richard L., et al.
Publicado: (2021)

Effects of Mu-Opiate Receptor Gene Polymorphism rs1799971 (A118G) on the Antidepressant and Dissociation Responses in Esketamine Nasal Spray Clinical Trials
por: Saad, Ziad, et al.
Publicado: (2020)

Study of Backsplash effects in the TRD tracker
por: Funk, W
Publicado: (1993)

Assessment of health-related quality of life and health status in patients with treatment-resistant depression treated with esketamine nasal spray plus an oral antidepressant
por: Jamieson, Carol, et al.
Publicado: (2023)

The TRD second-level trigger
por: Böck, R K, et al.
Publicado: (1990)

Usage of MSGC's in a TRD
por: Brons, S, et al.
Publicado: (1995)

Prototype tests for the ALICE TRD
por: Andronic, A., et al.
Publicado: (2001)

Prototype test for the ALICE TRD
por: Andronic, A, et al.
Publicado: (2000)

ALICE TRD trigger architecture
por: Angelov, V, et al.
Publicado: (2002)

Efficacy and Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Who Completed a Second Induction Period: Analysis of the Ongoing SUSTAIN-3 Study
por: Castro, Meredith, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_lvvi66mif718h1hrqgo32h096u